Volume 4.12 | Apr 2

Hematopoiesis News 4.12 April 2, 2013
Hematopoiesis News
     In this issue: Publications | ReviewsIndustry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
Apc Regulates the Function of Hematopoietic Stem Cells Largely through β-Catenin-Dependent Mechanisms
By genetic approach, scientists demonstrated that inactivation of β-catenin rescued the exhaustion of Apc-deficient hematopoietic stem/progenitor cells, thereby preventing bone marrow failure in Apc-deficient mice. [Blood] Abstract

NEW STEMvision CB, BM & MPB Algorithms
PUBLICATIONS (Ranked by impact factor of the journal)


Autoantigen Can Promote Progression to a More Aggressive TCL1 Leukemia by Selecting Variants with Enhanced B-Cell Receptor Signaling
(Auto)antigen engagement by the B-cell receptor and possibly the sites where this occurs influence the outcome of chronic lymphocytic leukemia. To test if selection for autoreactivity leads to increased aggressiveness and if this selection plays out equally in primary and secondary tissues, researchers used T-cell leukemia (TCL)1 cells reactive with the autoantigen phosphatidylcholine. [Proc Natl Acad Sci USA] Abstract | Full Article

Transposon Mutagenesis Reveals Cooperation of E-Twenty-Six Family Transcription Factors with Signaling Pathways in Erythro-Megakaryocytic Leukemia
To define genetic lesions driving leukemia, the authors targeted cre-dependent Sleeping Beauty transposon mutagenesis to the blood-forming system using a hematopoietic-selective vav 1 oncogene promoter. [Proc Natl Acad Sci USA] Abstract

mTOR Regulates DNA Damage Response through NF-κB-Mediated FANCD2 Pathway in Hematopoietic Cells
Researchers showed that gene targeting of mammalian target of rapamycin (mTOR) in hematopoietic stem/progenitor cells causes a defective DNA damage response (DDR) to a variety of DNA damage agents, mimicking that caused by deficient FANCD2, a key component of the Fanconi anemia (FA) DDR machinery. [Leukemia] Abstract

Global H3K4me3 Genome Mapping Reveals Alterations of Innate Immunity Signaling and Overexpression of JMJD3 in Human Myelodysplastic Syndrome CD34+ Cells
Data indicate the deregulation of trimethylated histone 4 lysine 3 (H3K4me3) and associated abnormal activation of innate immunity signals play a role in the pathogenesis of myelodysplastic syndromes (MDS) and that targeting these signals may have potential therapeutic value in MDS. [Leukemia] Abstract

Inosine Triphosphate Pyrophosphohydrolase (ITPA) Polymorphic Sequence Variants in Adult Hematological Malignancy Patients and Possible Association with Mitochondrial DNA Defects
Investigators hypothesized that reduced ITPA activity may cause acquired mitochondrial DNA (mtDNA) defects. Furthermore, they investigated whether accumulating mtDNA defects may then be a risk factor for cell transformation, in adult hematological malignancy. [J Hematol Oncol] Abstract | Full Article

The Src Homology 2 Protein Shb Promotes Cell Cycle Progression in Murine Hematopoietic Stem Cells by Regulation of Focal Adhesion Kinase Activity
The widely expressed adaptor protein Shb has previously been reported to contribute to T cell function due to its association with the T cell receptor and furthermore, several of Shb’s known interaction partners are established regulators of blood cell development and function. Researchers explored hematopoietic stem and progenitor cell function in the Shb knockout mouse. [Exp Cell Res] Abstract

Electrospun Nanofibers as a Bioadhesive Platform for Capturing Adherent Leukemia Cells
Researchers investigated the adhesive behaviors of normal and abnormal hematopoietic cells on nanotopographical materials. Previously, electrospun nanofiber scaffolds (NFS) were used to capture and expand hematopoietic stem cells in vitro; here they demonstrated that NFS could also serve as a useful bioadhesive platform for capturing functionally adherent leukemia cells. [J Biomed Mater Res A] Abstract


MRD-Directed Risk-Stratification Treatment May Improve Outcome of t (8;21) AML in the First Complete Remission: Results from AML05 Multicenter Trial
Researchers aimed to improve outcome of t (8;21) acute myeloid leukemia (AML) in first complete remission by applying risk-directed therapy based on minimal residual disease (MRD) determined by RUNX1/RUNX1T1 transcript levels. [Blood] Abstract

A Variant in IRF3 Impacts on the Clinical Outcome of AML Patients Submitted to Allo-SCT
Scientists analyzed two gene variants in IFN regulatory factor-3 (IRF3) (rs7251 and rs2304205) on the clinical outcome of 249 AML patients submitted to HLA-identical sibling allo-SCT. [Bone Marrow Transplant] Abstract

Etoposide in Combination with Low-Dose CAG (Cytarabine, Aclarubicin, G-CSF) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia: A Multicenter, Randomized Control Trial in Southwest China
In a well-controlled multi-center randomized trial in southwestern China, 228 patients with refractory or relapsed acute myeloid leukemia received a low-dose CAG regimen either with etoposide or without etoposide. The complete remission rate, overall survival and toxicity were evaluated. [Leuk Res] Abstract

Free Wallchart: Identification of Colonies Derived from Mouse Hematopoietic Progenitors

Advances in Stem Cell Therapy against Gliomas
Stem cell-based therapy using neural, mesenchymal, or hematopoietic stem cells may be an alternative approach because it is tumor selective and allows targeted therapy that spares healthy brain tissue. The authors discuss current trends and the latest developments in stem cell therapy against malignant gliomas from both the experimental laboratory and the clinic. [Trends Mol Med] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoietic research field.

Acceleron Receives Two FDA Orphan Designations for ACE-536
Acceleron Pharma, Inc. announced that the United States Food and Drug Administration (FDA) granted orphan designation for ACE-536 for the treatment of beta-thalassemia and for the treatment of myelodysplastic syndromes, two rare blood disorders characterized by severe and chronic anemia. [Acceleron Pharma, Inc.] Press Release

Pfizer’s BOSULIF® (bosutinib) Receives Conditional Marketing Authorization from the European Commission
Pfizer Inc. announced that the European Commission has granted conditional marketing authorization for BOSULIF® in the European Union for the treatment of adult patients with chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. [Pfizer Inc.] Press Release

Promising Stem Cell Therapy for Leukemia Patients
Leukemia patients receive a bone marrow transplant, which allows them to build a “new” immune system. However, this immune system not only attacks cancer cells but healthy tissue too. Special antibodies will be used to protect healthy tissue in future. [Fraunhofer-Gesellschaft] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)
Center for Biologics Evaluation and Research (United States)
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW 2013 In Vitro Biology Meeting
June 15-19, 2013
Providence, United States

Visit our events page to see a complete list of events in the hematopoietic community.


Postdoctoral Position – Stem Cell Research (University of Washington)

Lecturer or Reader – Associate Professor (University of Reading)

Research Assistant – Stem Cell & Leukemia Epigenetics (King’s College London)

Postdoctoral Position – Bioinformatics and Stem Cell Biology (University of Texas at Houston)

Postdoctoral Position – Stem Cells and Cancer (Tsinghua University)

Cord Blood Laboratory Manager (Puget Sound Blood Center)

Postdoctoral Positions (Cancer Science Institute of Singapore)

Postdoctoral Positions – Cell Death Signaling & Cancer (Goethe Universität Frankfurt, Institute for Experimental Cancer Research in Pediatrics)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us

Suite 201 – 375 West Fifth Avenue
Vancouver, BC V5Y 1J6, Canada